Neurocrine Biosciences, Inc.
NBIX
$107.00
-$3.60-3.26%
| Weiss Ratings | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Fair | |||
| Risk Grade | C | |||
| Reward Grade | B | |||
| Rating Factors | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Excellent | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.52 | |||
| Price History | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.79% | |||
| 30-Day Total Return | -6.97% | |||
| 60-Day Total Return | -21.61% | |||
| 90-Day Total Return | -8.89% | |||
| Year to Date Total Return | -22.39% | |||
| 1-Year Total Return | -24.32% | |||
| 2-Year Total Return | 10.20% | |||
| 3-Year Total Return | 15.23% | |||
| 5-Year Total Return | 16.82% | |||
| 52-Week High % Change | -28.37% | |||
| 52-Week Low % Change | 7.59% | |||
| Price | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $157.98 | |||
| 52-Week Low Price | $105.18 | |||
| 52-Week Low Price (Date) | Mar 11, 2025 | |||
| 52-Week High Price (Date) | Aug 01, 2024 | |||
| Valuation | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 11.28B | |||
| Enterprise Value | 10.70B | |||
| Price/Earnings (TTM) | 34.38 | |||
| Earnings Per Share (TTM) | 3.29 | |||
| Earnings Per Share Growth | 35.69% | |||
| Price/Earnings To Growth | 0.96 | |||
| Price/Sales (TTM) | 4.94 | |||
| Price/Book (Q) | 4.34 | |||
| Enterprise Value/Revenue (TTM) | 4.54 | |||
| Price | $107.00 | |||
| Enterprise Value/EBITDA (TTM) | 17.95 | |||
| Enterprise Value/EBIT | 18.81 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 102.90M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 617 7600 | |||
| Address | 12780 El Camino Real San Diego, CA 92130 | |||
| Website | www.neurocrine.com | |||
| Country | United States | |||
| Year Founded | 1992 | |||
| Profitability | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 24.15% | |||
| Profit Margin | 14.49% | |||
| Management Effectiveness | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 10.20% | |||
| Return on Equity | 14.16% | |||
| Income Statement | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.36B | |||
| Total Revenue (TTM) | 2.36B | |||
| Revenue Per Share | $22.89 | |||
| Gross Profit (TTM) | 1.59B | |||
| EBITDA (TTM) | 596.10M | |||
| EBIT (TTM) | 569.00M | |||
| Net Income (TTM) | 341.30M | |||
| Net Income Avl. to Common (TTM) | 341.30M | |||
| Total Revenue Growth (Q YOY) | 21.84% | |||
| Earnings Growth (Q YOY) | -30.20% | |||
| EPS Diluted (TTM) | 3.29 | |||
| EPS Diluted Growth (Q YOY) | -30.74% | |||
| Balance Sheet | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.08B | |||
| Cash Per Share (Q) | $10.46 | |||
| Total Current Assets (Q) | 1.72B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.59B | |||
| Current Ratio (Q) | 3.397 | |||
| Book Value Per Share (Q) | $26.05 | |||
| Total Assets (Q) | 3.72B | |||
| Total Current Liabilities (Q) | 507.70M | |||
| Total Debt (Q) | 495.70M | |||
| Total Liabilities (Q) | 1.13B | |||
| Total Common Equity (Q) | 2.59B | |||
| Cash Flow | NBIX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -126.80M | |||
| Cash from Financing (TTM) | -486.70M | |||
| Net Change in Cash (TTM) | -18.10M | |||
| Levered Free Cash Flow (TTM) | 395.94M | |||
| Cash from Operations (TTM) | 595.40M | |||
